Goudable J, Pollet J, DuBois J A
Université Lyon1, Inserm U870, HCL Lyon.
Ann Biol Clin (Paris). 2008 Nov-Dec;66(6):647-55. doi: 10.1684/abc.2008.0279.
Seven hospital-based glucose monitoring systems (meters) were evaluated with particular attention to those analytical interferences encountered in intensive care patients. Imprecision differed little between meters and remained altogether within acceptable limits. Inaccuracy, as measured by comparison with a hexokinase method presented with significant differences, yet without exceeding acceptable limits either. All meters but one showed an important bias when hematocrit departed from the reference interval. Two meters would not distinguish maltose from glucose. Three showed an important positive bias in the presence of acetaminophen and four a comparable bias in the presence of ascorbate. Only one meter was unaffected by both such exogenous interferences and hematocrit variations, owing to built-in hematocrit and electrochemical blank measuring devices. This meter also showed narrowest correlation with hexokinase methods. At a time when intensive care patients are being submitted to ever tighter glycemic control, it is desirable and our results show that it is now possible to tighten accordingly the acceptability criteria of glucose meters used to this end.
对七种基于医院的血糖监测系统（血糖仪）进行了评估，特别关注重症监护患者中遇到的那些分析干扰。血糖仪之间的不精密度差异不大，总体上仍在可接受范围内。与己糖激酶法相比测量的不准确程度存在显著差异，但也未超过可接受范围。除了一台血糖仪外，当血细胞比容偏离参考区间时，所有血糖仪都显示出明显的偏差。两台血糖仪无法区分麦芽糖和葡萄糖。三台血糖仪在存在对乙酰氨基酚时显示出明显的正偏差，四台血糖仪在存在抗坏血酸盐时显示出类似的偏差。由于内置了血细胞比容和电化学空白测量装置，只有一台血糖仪不受此类外源性干扰和血细胞比容变化的影响。该血糖仪与己糖激酶法的相关性也最窄。在重症监护患者的血糖控制越来越严格的时代，这样做是可取的，而且我们的结果表明，现在有可能相应地收紧用于此目的的血糖仪的可接受标准。
